Highlighs in MBC: Discussions

PALOMA-2

ASCO 2022

What are the cosenquences of the new OS data for CDK4/6…

D. Lüftner, W. Janni, N. Harbeck, E. Senkus, H. Rugo, S. Tolaney, G. Curigliano, P. Fasching

TROPiCS-02

ASCO 2022

More data needed: Are the results clinical meaningful?…

D. Lüftner, W. Janni, N. Harbeck, E. Senkus, H. Rugo, S. Tolaney, G. Curigliano, P. Fasching

ASCO 2022

Transatlantic differences in ADC side effects…

Hope Rugo, MD; Diana Lüftner, MD; Volkmar Müller, MD

Destiny-Breast04

ASCO 2022

Paradigm shift in breast cancer: Where do we use the…

D. Lüftner, W. Janni, N. Harbeck, E. Senkus, H. Rugo, S. Tolaney, G. Curigliano, P. Fasching

MAINTAIN

ASCO 2022

CDK4/6i switch: who benefits from switching the CDK4/6…

D. Lüftner, W. Janni, N. Harbeck, E. Senkus, H. Rugo, S. Tolaney, G. Curigliano, P. Fasching

MBC treatment Perspectives: Discussion

Destiny-Breast04

ASCO 2022

Determining HER2 receptor expression: How do we target…

D. Lüftner, V. Müller, B. Pistilli, N. Harbeck, F. Cardoso, V. Diéras, P. Fasching

Tropics02; Destiny-Breast04

ASCO 2022

Patients perspectives: ADCs - how do manage the new,…

D. Lüftner, V. Müller, B. Pistilli, N. Harbeck, F. Cardoso, V. Diéras, P. Fasching

TROPiCS-02

ASCO 2022

What clincial value has statistical signifcance? How…

D. Lüftner, V. Müller, B. Pistilli, N. Harbeck, F. Cardoso, V. Diéras, P. Fasching

Destiny-Breast04; U31402-A-J101; PALOMA-2; MAINTAIN

ASCO 2022

ADCs & CDK4/6i - paradigm shifts and therapy switches…

J. Cortes, D. Lüftner, P. Fasching

MAINTAIN

ASCO 2022

How to determine progress of disease? How to proceed…

D. Lüftner, V. Müller, B. Pistilli, N. Harbeck, F. Cardoso, V. Diéras, P. Fasching

Breast cancer metastatic: 100 seconds ENG

Tropics02; Destiny-Breast04

ASCO 2022

Fascinating data of ADCs in breast cancer at ASCO22

Véronique Diéras, MD

NRG-BR002

ASCO 2022

No effect for local treatment of metastasis

Andreas Schneeweiss, MD

Destiny-Breast04

ASCO 2022

Revolution in the field of HR+ disease

Giuseppe Curigliano, MD

PALOMA-2

ASCO 2022

Disappoiting final OS data and its implications for our…

Diana Lüftner, MD; Volkmar Müller, MD

MAINTAIN

ASCO 2022

First evidence on benefit of CDK4/6 inhibitors beyond…

Elzbieta Senkus-Konefka, MD

PALOMA-2

ASCO 2022

Possible explanations of the negative study

Andreas Schneeweiss, MD

FAKTION

ASCO 2022

Option for overcoming endocrine resistance?

Wolfgang Janni, MD

ASCO 2022

Patritumab Deruxtecan: HER3-targeted ADC in HER3…

Andreas Schneeweiss, MD

DESTINY-Breast04; TROPiCS-02

ASCO 2022

Breakthrough news with antibody drug conjugate

Michael Untch, MD

TROPiCS-02

ASCO 2022

Smart chemotherapy improves PFS

Giuseppe Curigliano, MD

Destiny-Breast04

ASCO 2022

Exciting and practice changing news for HR+/Her2low MBC…

Carmen Criscitiello, MD

Destiny-Breast04

ASCO 2022

New standard of care for HR+/Her2low patients

Karen Gelmon, MD

FAKTION

ASCO 2022

Improvment of PFS & OS with activated alteration…

Andreas Schneeweiss, MD

coopERA BC

ASCO 2022

Combi SERD + Palbo reduces proliferation better than…

Peter Fasching, MD

Destiny-Breast04

ASCO 2022

Gamechanger in breast cancer

Gil Morgan, MD

MAINTAIN

ASCO 2022

Benefit of CDK4/6 Switch after Progression

Wolfgang Janni, MD

TROPICS-02; Destiny-Breast04

ASCO 2022

Exciting advances across a wide subset of breast…

Hope Rugo, MD

PALOMA-2; MAINTAIN

ASCO 2022

No changes in clinical practice after new CDK4/6i-data

Alessandra Gennari, MD

Destiny-Breast04

ASCO 2022

T-DxD should be the new SoC for Her2low MBC patients

Sara Tolaney, MD

Tropics02

ASCO 2022

SG is a new therapy option for HR+/HER2- MBC patients

Carmen Criscitiello, MD

Destiny-Breast04

ASCO 2022

New SoC for large subpopulation of breast cancer…

Elzbieta Senkus-Konefka, MD

TROPiCS-02

ASCO 2022

ADC: future therapeutic option in advanced HR+/HER2 BC

Wolfgang Janni, MD

BioItaLEE

ASCO 2022

Combination of ctDNA and TKa assesment may improve…

Carmen Criscitiello, MD

ASTER

ASCO 2022

Endocrine therapy alone is important in treatment of…

Karen Gelmon, MD

DESTINY-Breast04; TROPiCS-02

ASCO 2022

New agents for the clincial practice

Javier Cortes, MD

MAINTAIN

ASCO 2022

Additional administration of ribociclib improves PFS…

Andreas Schneeweiss, MD

Destiny-Breast04, Destiny-Breast03, TROPiCS-2, PALOMA-2, MAINTAIN, NRG-BR002

ASCO 2022

My ASCO22 highlights in metastatic breast cancer

Fatima Cardoso, MD

Tropics02

ASCO 2022

Good therapeutic option in HR+ HER2- mBC after failure…

Andreas Schneeweiss, MD

Destiny-Breast04

ASCO 2022

Practice changing data

Nadia Harbeck, MD

NRG-BR002

ASCO 2022

Oligometastasis: no advantage of additional…

Wolfgang Janni, MD

PALOMA-2

ASCO 2022

Palbociclib - Overall survival data

Nadia Harbeck, MD

NeoSTAR

ASCO 2022

Sacituzumab govitecan improves PCr in patients with…

Sara Tolaney, MD

NRG-BR002

ASCO 2022

Discontiunation of trial is disappointing despite…

Karen Gelmon, MD

TROPiCS-02

ASCO 2022

SG may be a good option for pre-treated HR+/Her2- pts

Sara Tolaney, MD

Destiny-Breast 04; Tropics-02

ASCO 2022

Impressive and practice changing data of ADCs mark the…

Barbara Pistilli, MD

Breast Cancer metastatic: 100 seconds Multi Language

DESTINY-Breast04; TROPiCS-02

ASCO 2022

ADCs en cáncer de mama con receptores hormonales…

Javier Cortes, MD

Destiny-Breast04, Tropics-02

ASCO22

Noutăți inovatoare cu conjugatul de medicamente cu…

Michael Untch, MD

MAINTAIN

ASCO 2022

Pierwsze dane nt. skuteczności inhibitorów CDK4/6 po…

Elzbieta Senkus-Konefka, MD

Destiny-Breast04

ASCO 2022

Una rivoluzione per il tumore mammario…

Giuseppe Curigliano, MD

Destiny-Breast 04; Tropics-02

ASCO 2022

Les nouvelles données impressionnantes des ADC à l’ASCO…

Barbara Pistilli, MD

Destiny-Breast04

ASCO 2022

Nowy standard dla znaczącej subopulacji chorych na raka…

Elzbieta Senkus-Konefka, MD

Tropics02

ASCO 2022

SG come nuova opzione di cura per le pazienti con…

Carmen Criscitiello, MD

Destiny-Breast04

ASCO 2022

Novità entusiasmanti e practice changing per le…

Carmen Criscitiello, MD

PALOMA-2; MAINTAIN

ASCO 2022

PALOMA2 e MAINTAIN: cosa cambia nella pratica clinica?

Alessandra Gennari, MD

Destiny-Breast 04; Tropics-02

ASCO 2022

I nuovi impressionanti risultati degli ADC a l’ASCO…

Barbara Pistilli, MD

BioItaLEE

ASCO 2022

La valutazione combinata di ctDNA e TKa può aiutare a…

Carmen Criscitiello, MD

TROPiCS-02

ASCO 2022

Il sacituzumab govitecan migliora il PFS nei tumori…

Giuseppe Curigliano, MD

Early breast Cancer: Discussions

ASTRRA

ASCO 2022

Ovarian function suppression - it is here to stay!

C. Criscitiello, A. Schneeweiss, A. Gennari, K. Gelmon, M. Untch, N. Harbeck

Aster 70s

ASCO 2022

CT benefit for elderly patients, if they are able to…

N. Harbeck, K. Gelmon, C. Criscitiello, A. Schneeweiss, A. Gennari, M. Untch

LUMINA

ASCO 2022

Adding towards deescalation in luminal A EBC by…

N. Harbeck, A. Gennari, K. Gelmon, C. Criscitiello, M. Untch

ABCSG-18

ASCO 2022

Long term overall survival benefit of Denosumab in…

A. Schneeweiss, N. Harbeck, K. Gelmon, C. Criscitiello, A. Schneeweiss, A. Gennari, M. Untch

KEYNOTE-522; NeoSTAR

ASCO 2022

Neoadjuvant Pembro decreased RCB. SG - first promising…

N. Harbeck, C. Criscitiello, K. Gelmon, A. Gennari, M. Untch

Breast cancer early: 100 seconds

iSPY-2, Keynote-522, ASTER-70s, ASTRRA, ABCSG-18

ASCO 2022

My ASCO22 highlights in early breast cancer

Fatima Cardoso, MD

ADAPT

ASCO 2022

High concordance of local, central IHC and RT-PCR for…

Nadia Harbeck, MD

coopERA BC

ASCO 2022

Combi SERD + Palbo redzuert proliferation better than…

Peter Fasching, MD

NSCLC metastatic: Discussion

KRYSTAL-1

ASCO 2022

Molecular landscape - Part 1

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

Lung-MAP

ASCO 2022

Immunotherapy - Part 2

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

CHRYSALIS-2; CHRYSALIS

ASCO 2022

Molecular landscape - Part 2

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

CheckMate 227; CheckMate 9LA; FDA pooled

ASCO 2022

Immunotherapy - Part 1

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

NSCLC metastatic: 100 Seconds ENG

ASCO 2022

CLN-081 is a promising new agent for EGFR exon 20…

Stephen, Liu, MD

COSMIC-021

ASCO 2022

COSMIC-021: Not practice-changing, but interesting…

Sacha Rothschild, MD

CHRYSALIS

ASCO 2022

New treatment options for METexon 14 skipping:…

Lizza Hendriks, MD

CHRYSALIS-2; CHRYSALIS

ASCO 2022

New components and therapies for advanced NSCLC

Noemi Reguart, MD

KRYSTAL-1

ASCO 2022

In the second line: Options for Immunotherapy…

Noemi Reguart, MD

FDA pooled analysis

ASCO 2022

PD-L1 over 50%: Chemo-IO or IO?

Riyaz Shah, MD

KRYSTAL-1

ASCO 2022

Promising results for pre-treated patients with…

Lizza Hendriks, MD

CHRYSALIS

ASCO 2022

New option in patients harboring METex14 mutation

Nicolas Girard, MD

CodeBreaK100

ASCO 2022

Multiple aquired resistance mutations may drive disease…

Riyaz Shah, MD

ASCO 2022

CLN-081 for patients with metastatic NSCLC and an…

Lizza Hendriks, MD

CHRYSALIS

ASCO 2022

Bispecific Antibodies - the cMET field is moving

Michael Thomas, MD

CHRYSALIS-2

ASCO 2022

A chemo-free option in patients with EGFR-mutation

Stephen Liu, MD

Lung-MAP; KRYSTAL-1

ASCO 2022

Options after progression to chemo/IO and for KRASG12C…

Hossein Borghaei, MD

CHRYSALIS

ASCO 2022

Amivantamab as a future option for METex14 patients?

Stephen Liu, MD

FDA pooled analysis

ASCO 2022

Strategies for PD-L1 > 50%

Hossein Borghaei, MD

FDA pooled

ASCO 2022

Role of IO and chemo-IO in patients with PD-L1 > 50%

Sacha Rothschild, MD

KRYSTAL-1

ASCO 2022

Is adagrasib an alternative to sotorasib?

Riyaz Shah, MD

KRYSTAL-1

ASCO 2022

KRASG12C mutation: Adagrasib is comparabale to…

Nicolas Girard, MD

NSCLC metastatic: 100 seconds Multi Language

KRYSTAL-1

ASCO 2022

L’adagrasib, inhibiteur de la mutation KRASG12C: une…

Nicolas Girard, MD

FDA pooled

ASCO 2022

Die Rolle von IO und Chemo-IO bei Patienten mit PD-L1 >…

Sacha Rothschild, MD

CHRYSALIS-2; CHRYSALIS

ASCO 2022

Nuevas terapias para el CPCNP avanzado

Noemi Reguart, MD

CHRYSALIS

ASCO 2022

Nieuwe behandelopties voor METexon 14 skipping:…

Lizza Hendriks, MD

KRYSTAL-1; Lung-MAP

ASCO 2022

Segunda Linea: opciones tras resistencia a…

Noemi Reguart, MD

KRYSTAL-1

ASCO 2022

Veelbelovende resultaten voor voorbehandelde patienten…

Lizza Hendriks, MD

ASCO 2022

Bispezifische Antikörper - Neues von CHRYSALIS

Michael Thomas, MD

ASCO 2022

CLN-081 voor patienten met gemetastaseerd NSCLC en een…

Lizza Hendriks, MD

CHRYSALIS

ASCO 2022

Une nouvelle option, l’amivantamab, en situation de…

Nicolas Girard, MD

COSMIC-021

ASCO 2022

COSMIC-021: Nicht praxisverändernd, aber interessante…

Sacha Rothschild, MD

ASCO 2022

PD-L1 über 50 % - was tun?

Michael Thomas, MD

ASCO 2022

Was tun nach Versagen einer Chemoimmun-Therapie?

Michael Thomas, MD

NSCLC early stages: Discussion

NADIM II; CheckMate 816

ASCO 2022

Neoadjuvant and adjuvant therapy - Part 1

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

NADIM II; CheckMate 816

ASCO 2022

Neoadjuvant and adjuvant therapy - Part 2

F. Griesinger, M. Reck, M. Thomas, L. Hendriks, N. Reguart, N. Girard, D. Moro-Sibilot, R. Shah, S. Rothschild

NSCLC early stages: 100 seconds

NADIM-II

ASCO 2022

NADIM-II strengthens the findings from CheckMate-816

Gil Morgan, MD

NADIM II

ASCO 2022

A new option in neoadjuvant chemoimmunotherapy

Denis Moro-Sibilot, MD

KEYNOTE-799

ASCO 2022

New treatment approaches in Stage III

Martin Reck, MD

CheckMate-816

ASCO 2022

CheckMate-816: Neoadjuvant therapy

Frank Griesinger, MD

NADIM II

ASCO 2022

Perspectives on multimodality

Michael Thomas, MD

NSCLC early stages: 100 seconds Multi Language

NADIM II

ASCO 2022

Chimiothérapie néoadjuvante des stades III , vers un…

Denis Moro-Sibilot, MD

KEYNOTE-799

ASCO 2022

Neue Ansätze im Stadium III

Martin Reck, MD

SCLC: 100 Seconds ENG

ASCO 2022

Immuncheckpoint-inhibitor therapy

Frank Griesinger, MD

SKYSCRAPER-02

ASCO 2022

SKYSCRAPER-02: Subgroups could be important

Michael Thomas, MD

SKYSCRAPER-02

ASCO 2022

SCLC-Update: No benefit with Tiragolumab/Chemo-IO is…

Denis Moro-Sibilot, MD

SKYSCRAPER-02

ASCO 2022

No benefit for tiragolumab / novel anti-PD-1 mAB…

Sacha Rothschild, MD

SCLC: 100 seconds Multi Language

SKYSCRAPER-02

ASCO 2022

Le Tiragolumab n’apporte pas de bénéfice à la…

Denis Moro-Sibilot, MD

Prostate Cancer: Discussions

TheraP; VISION

ASCO 2022

mCRPC: LuPSMA - new treatment option in mCRPC

M.-O. Grimm, D. Murphy, A. Bjartell, E. Efstathiou, G. Morgan, N. Shore

Propel; MAGNITUDE; BRCAAWAY

ASCO 2022

PARP inhibitors in mCRPC: Do we need more genetic…

M.-O. Grimm, A. Bjartell, E. Efstahiou, G. Morgan, N. Shore

ENZAMET; ARASENS

ASCO 2022

mHSPC: Transatlantic differences in genetic testing &…

A. Merseburger, A. Morgans, E. Efstahiou, D. Murphy, N. Shore, A. Bjartell

Prostate Cancer: 100 seconds ENG

VISION

ASCO 2022

SUV mean at PET images as a prognostic tool for PSMA…

Anders Bjartell, MD

ASCO 2022

Surrogate endpoints in mHSPC

Anders Bjartell, MD

ASCO 2022

Ongoing trial invetiagting the impact of…

Neal Shore, MD

ENZAMET

ASCO 2022

ADT alone is no longer standard of care

Alicia Morgans, MD

ARASEC

ASCO 2022

Value of triple-therapy - complimentary study to…

Neal Shore, MD

TheraP

ASCO 2022

3 year overall survival of TheraP study

Anders Bjartell, MD

TheraP

ASCO 2022

LuPSMA & cabazitaxel are better than SoC alone

Declan Murphy, MD

TheraP

ASCO 2022

TheraP shows no difference in overall survival between…

Gil Morgan, MD

BRCAAWAY

ASCO 2022

Arbiraterone + Olaparib: Is it synergistic?

Alicia Morgans, MD

Vision

ASCO 2022

SUVmean is highly predictive of better PFS and OS

Declan Murphy, MD

ASCO 2022

PFS good surrogate endpoint for overall survival

Axel Merseburger, MD

VISION

ASCO 2022

Further updates from the VISION trial

Alicia Morgans, MD

ENZAMET

ASCO 2022

No big scoop, but encouraging results

Yohann Loriot, MD

CHART

ASCO 2022

SHR3680 - do we need a new androgen receptor inhibitor

Axel Merseburger, MD

ASCO 2022

Phase 1 study on combining LuPSMA treatment with…

Anders Bjartell, MD

ENZAMET

ASCO 2022

The efficacy of doublets in mHSPC

Gil Morgan, MD

ASCO 2022

GGT impacts PCa patients care

Neal Shore, MD

The highlights in GU cancers of ASCO22

ASCO 2022

The highlights in GU cancers of ASCO22

Ignacio Duran, MD

ARAMIS

ASCO 2022

Frequent imaging for early detection of metastases in…

Marc-Oliver Grimm, MD

VISION

ASCO 2022

Lu-PSMA effective regardless of prior or concomitant…

Axel Merseburger, MD

TheraP

ASCO 2022

Lu-PSMA in the third line

Axel Merseburger, MD

Prostate Cancer: 100 seconds Multi Language

ASCO 2022

Tidigare endpoints I mHSPC studier

Anders Bjartell, MD

ASCO 2022

Kombination av 177-LU-PSMA-617 och pembrolizumab I Fas…

Anders Bjartell, MD

ASCO 2022

Pas de nouvelles sensationnelles mais des données…

Yohann Loriot, MD

VISION

ASCO 2022

Kvantifiering av PMSA PET upptaget som prognostisk…

Anders Bjartell, MD

ASCO 2022

Lo mas destacado en tumores GU en ASCO 2022

Ignacio Duran, MD

TheraP

ASCO 2022

Treårs överlevnadsresultat i TheraP studien.

Anders Bjartell, MD

Kidney Cancer: Discussion

CLEAR Study; KEYNOTE-426; CheckMate (CM) 214; CheckMate 9ER

ASCO 2022

Combination Therapy is State of the Art in Metastatic…

Philipp Iavnyi, MD; Laura-Maria Krabbe, MD

CheckMate9ER

ASCO 2022

What are the consequences for future trial design?

P. Ivanyi, P. Goebell, I. Duran, H. Hammers, P. Grivas

EVEREST

ASCO 2022

EVEREST: Inisghts from the negative trial

P. Ivanyi, P. Goebell, I. Duran, H. Hammers, P. Grivas

CheckMate214

ASCO 2022

The relevance of quality of life in kidney cancer!

P. Ivanyi, P. Goebell, I. Duran, H. Hammers, P. Grivas

Kidney Cancer: 100 seconds ENG

KEYNOTE-426

ASCO 2022

Combi Axi + Pembro also successful with good risk…

Axel Merseburger, MD

EVEREST

ASCO 2022

Should we be looking at Everolimus in the future?

Tom Powles, MD

EVEREST

ASCO 2022

Should Everolimus be revisited for high-risk patients?

Hans Hammers, MD

LITESPARK-004

ASCO 2022

Belzutifann shows good tumor activity in renal cancer

Axel Merseburger, MD

LITESPARK-004

ASCO 2022

Clear evidence for durable benefit for patients with…

Hans Hammers, MD

CheckMate 9ER

ASCO 2022

Depth of remission in firstline

Philipp Ivanyi, MD

ASCO 2022

PSMA-PET may improve imaging of clear cell RCC

Hans Hammers, MD

CheckMate 9ER; CheckMate 214

ASCO 2022

QoL & DepOR correlate with clinical outcomes - reminder…

Hans Hammers, MD

The highlights in GU cancers of ASCO22

ASCO 2022

The highlights in GU cancers of ASCO22

Ignacio Duran, MD

ASCO 2022

Importance of health related quality of life

Philipp Ivanyi, MD

Kidney Cancer: 100 seconds - Multi Language

ASCO 2022

Lo mas destacado en tumores GU en ASCO 2022

Ignacio Duran, MD

ASCO 2022

Pas de nouvelles sensationnelles mais des données…

Yohann Loriot, MD

Bladder Cancer: Discussions

EV-103; RC-48

ASCO 2022

ADCs: do we enter a new era of therapy for urothelial…

L.-M. Krabbe, M.-O. Grimm, J. Bellmunt, Y. Loriot, T. Powles

COSMIC-021

ASCO 2022

New data on TKi utilization in bladder cancer

Laura-Maria Krabbe, MD; Marc-Oliver Grimm, MD

AURA; SAKK 06/17; JAVELIN

ASCO 2022

The role of systemic treatment in the pre-operative…

L.-M. Krabbe, M.-O. Grimm, J. Bellmunt, Y. Loriot, T. Powles

Bladder Cancer: 100 seconds ENG

ENZAMET

ASCO 2022

No big scoop, but encouraging results

Yohann Loriot, MD

SAKK 06/17

ASCO 2022

Perioperative immuno-chemotherapy in MIBC

Laura-Maria Krabbe, MD

ASCO 2022

ADCs: News from ASCO 2022

Philipp Ivanyi, MD; Peter Goebell, MD

QUILT 3.032; SWOG S1314

ASCO 2022

My highlights in localized urothelial cancer

Petros Grivas, MD

The highlights in GU cancers of ASCO22

ASCO 2022

The highlights in GU cancers of ASCO22

Ignacio Duran, MD

ASCO 2022

BCG failure

Philipp Ivanyi, MD

COSMIC-021; ATLANTIS

ASCO 2022

The end of of VEGF-targeted therapy in urothelial…

Tom Powles, MD

EV-301; RC48-ADC

ASCO 2022

Exciting future for ADCs

Tom Powles, MD

ASCO 2022

Maintenance concepts

Philipp Ivanyi, MD

CREST cohort B

ASCO 2022

Investigating sasanlimab in BCG-unresponsive NMIBC

Neal Shore, MD

ATLANTIS; MAIN_CAV

ASCO 2022

My highlights of metastasized urothelial cancer

Petros Grivas, MD

Bladder Cancer: 100 seconds - Multi Language

ASCO 2022

Σημαντικά μηνύματα για τον ουροθηλιακό καρκίνο από το…

Petros Grivas, MD

ASCO 2022

Lo mas destacado en tumores GU en ASCO 2022

Ignacio Duran, MD

Varia

ASCO 2022

Precision oncology - NTRK worth to search the patients

Philipp Ivanyi, MD

ASCO 2022

Systemic therapy

Philipp Ivanyi

ASCO 2022

Radiotherapy as a new standard for cisplatin ineligible…

Philipp Ivanyi, MD

ASCO22

Opportunities & challenges of cancer genetics

C. Moisidis-Tesch, MD; L.P. Shulman, MD

ASCO 2022

News from Sarcoma

Philipp Ivanyi, MD

ASCO 2022

Few testicular tumors after 5 years

Axel Merseburger, MD